BeiGene Announces Abstracts to be Presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

BEIJING, Oct. 28, 2015 (GLOBE NEWSWIRE) -- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer, announced today that it will present two abstracts at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The conference will take place November 5–9 at the Hynes Convention Center in Boston, Massachusetts. Details for the presentations are provided below.

1. Abstract #PR11: Phase 1 Study of a Novel PARP1/2 Selective Inhibitor, BGB-290

Authors: Jason Lickliter, Hui Gan, Tarek Meniawy, Jason Yang, Lai Wang, Lusong Luo, Michael Millward

This abstract has been selected as a late-breaker oral presentation and is featured in the press program.

  • Session Title: Spotlight on Proffered Papers: Session 3
  • Date: Sunday, November 8
  • Time: 3:46 PM – 3:57 PM EST
  • Location: Veterans Auditorium

2. Abstract #A91: BGB-283 Exhibits Potentials in Enhancing Tumor Immune Sensitization and Lymphocyte Function

Authors: Xi Yuan, Mi Lian, Xiaoran Wu, Lusong Luo

Nonclinical studies will be presented on the immunomodulation activity of BGB-283. BGB-283 is currently in dose-expansion studies.

  • Session Title: Immune Modulators
  • Date: Friday, November 6
  • Time: 12:15 PM – 3:15 PM EST
  • Location: Session A, Hall C-D

About BeiGene

BeiGene is a global, clinical-stage, research-based company focused on targeted and immuno-oncology therapeutics. With a team of 175+ scientists and staff, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is working to create combination solutions that will have both a meaningful and lasting impact on cancer patients. For more information, please visit our website at

CONTACT: Media/Investor Contact: Xin Huang US: +1 917-617-4653 China: +86 185-1406-3050

Source:BeiGene Ltd.